Savara (STU:YB4P) E10: €-1.60 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:YB4P Savara Inc STU:YB4P
36 GF Score
Price €4.81
! 3 Warning Signs
View Full Analysis

What is Savara E10?

Savara STU:YB4P -0.35% 36 E10 is €-1.60 as of Mar. 2026. GuruFocus rates STU:YB4P with a GF Score™ of 36/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Savara's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.130. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.60 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 35.40% per year. During the past 5 years, the average E10 Growth Rate was 28.90% per year. During the past 10 years, the average E10 Growth Rate was 38.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Savara was 54.20% per year. The lowest was 6.60% per year. And the median was 26.75% per year.

As of today (2026-07-19), Savara's current stock price is €4.81. Savara's E10 for the quarter that ended in Mar. 2026 was €-1.60. Savara's Shiller PE Ratio of today is .


Savara  (STU:YB4P) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Savara E10 Related Terms


Savara E10 Historical Data

* Premium members only.

The historical data trend for Savara's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Savara E10 Chart

Savara Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.92 -8.18 -5.93 -4.38 -2.13

Savara Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.76 -2.92 -2.47 -2.13 -1.60

STU:YB4P vs SPTX, EYPT, MNKD: E10 Comparison

For the Biotechnology subindustry, Savara's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Savara's Shiller PE Ratio falls into.


STU:YB4P
36GF Score
Savara Inc STU:YB4P
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Savara E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Savara's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.13/330.2130*330.2130
=-0.130

Current CPI (Mar. 2026) = 330.2130.

Savara Quarterly Data

per share eps CPI Adj_EPS
201606 -1.753 241.018 -2.402
201609 -1.078 241.428 -1.474
201612 -1.327 241.432 -1.815
201703 -1.543 243.801 -2.090
201706 -0.801 244.955 -1.080
201709 -0.235 246.819 -0.314
201712 -0.194 246.524 -0.260
201803 -0.697 249.554 -0.922
201806 -0.317 251.989 -0.415
201809 -0.309 252.439 -0.404
201812 -0.255 251.233 -0.335
201903 -0.301 254.202 -0.391
201906 -0.504 256.143 -0.650
201909 -0.272 256.759 -0.350
201912 -0.648 256.974 -0.833
202003 -0.244 258.115 -0.312
202006 -0.142 257.797 -0.182
202009 -0.153 260.280 -0.194
202012 -0.189 260.474 -0.240
202103 -0.109 264.877 -0.136
202106 -0.058 271.696 -0.070
202109 -0.060 274.310 -0.072
202112 -0.062 278.802 -0.073
202203 -0.045 287.504 -0.052
202206 -0.057 296.311 -0.064
202209 -0.071 296.808 -0.079
202212 -0.066 296.797 -0.073
202303 -0.065 301.836 -0.071
202306 -0.065 305.109 -0.070
202309 -0.094 307.789 -0.101
202312 -0.073 306.746 -0.079
202403 -0.101 312.332 -0.107
202406 -0.111 314.175 -0.117
202409 -0.099 315.301 -0.104
202412 -0.124 315.605 -0.130
202503 -0.111 319.799 -0.115
202506 -0.121 322.561 -0.124
202509 -0.119 324.800 -0.121
202512 -0.111 324.054 -0.113
202603 -0.130 330.213 -0.130

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.60 mean?
Savara (STU:YB4P) has a E10 of €-1.60 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Savara and its competitors.
Is Savara's E10 too high?
Savara's current E10 is €-1.60. Overall, Savara has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Savara's E10 compare to SPTX and EYPT?
Savara's E10 of €-1.60 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Savara and its competitors. Savara's current E10 is €-1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Savara stock overvalued right now?
Savara (STU:YB4P) has a current E10 of €-1.60. The current E10 is €-1.60. Savara's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Savara (STU:YB4P), the current E10 is €-1.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Savara Business Description

Other Exchanges SVRA:USA
Address 1717 Langhorne Newtown Road, Suite 300, One Summit Square, Langhorne, PA, USA, 19047
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
36GF Score

Get the complete analysis for STU:YB4P

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.81
Price